AP NEWS

Integra® XT Revision Total Ankle Replacement System Offers Innovative Solution to Ankle Arthroplasty Revision Surgery

November 20, 2018

PLAINSBORO, N.J., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company, today announced one of the first surgeries with the Integra® XT Revision Total Ankle Replacement System.

“Integra’s new total ankle revision system is designed to provide surgeons with stable tibial fixation through a narrow, finned tibia. I appreciate the anterior surgical approach, which is mindful of the blood supply,” said Dr. Christopher Ritter, a foot and ankle surgeon in Buffalo, New York. “I have performed several revision procedures with the XT Revision System and found that it is easy to implant and provides stable fixation. My patients are happy with their early outcomes.”

The Integra XT Revision Total Ankle Replacement System is one of the first FDA cleared devices indicated for revision ankle arthroplasty only and can be used to revise any commercially available primary total ankle replacement system. Key implant features include:

-- An augmented posterior sloped talus which addresses subsidence by rebuilding posterior talar height. -- An anatomic design that mimics the natural kinematics of the ankle, designed to promote a more normal gait and better overall function post-operatively.

“The launch of the Integra XT Revision Total Ankle Replacement System represents Integra’s commitment to further advance ankle arthroplasty solutions,” said Robert T. Davis, Jr., corporate vice president and president, Orthopedics and Tissue Technologies. “Many of our surgeons have expressed their excitement for the XT system and our approach for ankle revision surgery. With this addition to our ankle reconstruction portfolio, Integra now offers comprehensive care for end-stage ankle arthritis patients.”

The Integra XT Revision Total Ankle Replacement System was developed in partnership with five world leading foot and ankle surgeons – Dr. Michel Bonnin, (Lyon, France), Dr. Chris Coetzee (Eagan, Minnesota), Dr. Jean Alain Colombier (Toulouse, France), Thierry Judet, PhD (Paris, France), and Dr. Mark Myerson (Baltimore, Maryland). It is available in the U.S. through Integra’s Extremity Orthopedics sales team.

About Integra XT Revision Total Ankle Replacement SystemIntegra XT is indicated as a total ankle replacement in revision surgeries only for patients with ankle joints damaged by severe rheumatoid, post-traumatic, or degenerative arthritis. Components are intended for cemented use only.

About IntegraIntegra LifeSciences is a global leader in regenerative technologies, neurosurgical and extremity orthopedic solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel®, Bactiseal®, Cadence®, Certas™, Codman®, CUSA®, DuraGen®, DuraSeal®, ICP Express®, Integra®, MediHoney®, MicroFrance®, PriMatrix®, Salto Talaris®, SurgiMend®, TCC-EZ®, Titan™ and VersaTru™. For the latest news and information about Integra and its brands, please visit www.integralife.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading “Risk Factors” included in Item IA of Integra’s Annual Report on Form 10-K for the year ended December 31, 2017 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: Integra LifeSciences Holdings Corporation

InvestorsSravan Emany (609) 936-2488 sravan.emany@integralife.com Michael Beaulieu609-750-2827 michael.beaulieu@integralife.com

Media Laurene Isip609-750-7984 laurene.isip@integralife.com

AP RADIO
Update hourly